ClinicalTrials.gov
public full text
Public Domain
TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with anti-VEGF (Bevacizumab Biosimilar) in patients with BCLC-B stage hepatocellular carcinoma beyond up-to-seven criteria.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC#1323588
- Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)#895856
- TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC#1296206
- HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B#1363526
- TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC#880913
Record · ID 1228134
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive